STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) — Abbott Cooper PLLC is investigating Sutro Biopharma, Inc. (Nasdaq: STRO) (“Sutro” or the “Company”) on behalf of the Company’s investors.
The investigation seeks to determine whether Sutro’s board of directors has violated its fiduciary duty by instituting measures intended to interfere with the ability of Sutro stockholders to elect directors of their choosing.
Sutro stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing ac@abbottlawyer.com or visiting our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.
Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy. For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com.
CONTACT:
Abbott Cooper PLLC
Abbott Cooper
(475) 333-0674
www.abbottlawyer.com
Attorney advertising. Prior results do not guarantee a similar outcome.
- Telix Reports US$186M Q1 Revenue, Up 62% YOY - April 22, 2025
- Danske Bank share buy-back programme: transactions in week 16 - April 22, 2025
- 1STBIO and LigaChemBio Announce Strategic R&D and Licensing Option Agreement - April 22, 2025
